Richard S, Virsolvy A, Fort A
Inserm U637, physiopathologie cardiovasculaire, CHU Arnaud-de-Villeneuve, 371, avenue du Doyen-Faston-Giraud, 34295 Montpellier cedex 5, France.
Ann Cardiol Angeiol (Paris). 2008 Jun;57(3):166-73. doi: 10.1016/j.ancard.2008.02.019. Epub 2008 Jun 4.
The calcium (Ca2+) channel antagonists (CCA) are used successfully in the treatment of hypertension and angina pectoris. Their mode of action is to decrease Ca2+ entry in the vascular smooth muscle cells. Their molecular targets are voltage activated Ca2+ channels (VACC), especially the L-type (VACC-L). This review examines the role of the VACC-L and of the T-type (VACC-T) in vascular physiology and hypertension. The molecular mechanisms at the base of the vascular selectivity of CCA are presented with, in filigree, the concern of trying to understand the effect of recently developed molecules. In particular, we will examine the ideas having recently emerged concerning the mode of action of last generation dihydropyridines (DHPs) stripped of some of the undesirable effects of prototypes AC considered as highly specific of the VACC-L. These properties could result, in particular, from their effects on the VACC-T, which could occur in addition to those classically observed on the VACC-L.
钙（Ca2+）通道拮抗剂（CCA）已成功用于治疗高血压和心绞痛。其作用方式是减少Ca2+进入血管平滑肌细胞。它们的分子靶点是电压激活的Ca2+通道（VACC），尤其是L型（VACC-L）。本文综述了VACC-L和T型（VACC-T）在血管生理和高血压中的作用。介绍了CCA血管选择性的分子机制，并详细探讨了试图理解最近开发的分子的作用效果。特别是，我们将研究最近出现的关于新一代二氢吡啶（DHP）作用方式的观点，这些新一代二氢吡啶去除了被认为是VACC-L高度特异性的原型药物的一些不良作用。这些特性尤其可能源于它们对VACC-T的作用，这可能除了在VACC-L上经典观察到作用之外还会发生。
